| Value | ₹49.92 Cr |
|---|
BSE filing, NSE: KILITCH. Summary written from the filing by ALFA Finder's alert engine.
Kilitch Drugs(I) Ltd: key numbers
- Share price
- ₹201.32
- Market cap
- ₹703.9 Cr
- Revenue (annual)
- ₹235.5 Cr
- Net profit (annual)
- ₹30.17 Cr
- P/E (TTM)
- 23.4×Sector 45.9×
- Promoter holding
- 63.77%+0.00% QoQ
- FII holding
- 0.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kilitch Drugs(I) Ltd
All →Kilitch Drugs(I) Annual General Meeting
Kilitch Drugs' EGM notice seeks shareholder approval for selling its Ethiopian material subsidiary and converting subsidiary debt into equity. It also proposes two independent director appointments.
Kilitch Drugs(I) Merger & Restructuring Worth ₹131.6 Cr
Kilitch Drugs will divest its entire Ethiopian subsidiary stake to HarmeeCare for US$14 million (~₹131.6 Crore). Proceeds will fund debt repayment and Pen plant expansion.
- Value
- ₹131.6 Cr
Kilitch Drugs(I) Merger & Restructuring Worth ₹120.8 Cr
Kilitch Drugs will divest its 100% stake in subsidiary Kilitch Estro Biotech PLC for USD 12.855 million (approx. ₹120.84 Crore).
- Value
- ₹120.8 Cr
- From
- HarmeeCare Pharmaceuticals
Kilitch Drugs(I) Management Change
Kilitch Drugs' Non-Executive Independent Director Mr. Venkita Subramanian Rajan resigned effective 21 Oct 2026. He also stepped down from the Audit, NCR, and SRC Committees citing personal commitments.
Kilitch Drugs(I) Other Announcement
Kilitch Drugs (India) Limited submitted its quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September, 2026.
Kilitch Drugs(I) Annual General Meeting
Kilitch Drugs (India) held its 34th Annual General Meeting on August 27, 2026, transacting four business resolutions including financial statement approval and director re-appointment.
Other other announcement announcements
All →Maharaja & Speedex India Other Announcement
Maharaja & Speedex India filed its quarterly shareholding pattern as of 18 September 2026 under Regulation 31. It shows promoter and public holdings with no transaction or capital event.
Trio Mercantile & Trading Other Announcement
Trio Mercantile & Trading filed its quarterly shareholding pattern for the period ended 30 September 2026. The filing reports promoter and public holdings only, with no transaction or corporate event.
Pace Digitek Other Announcement
Pace Digitek submitted the Crisil Ratings monitoring agency report for the quarter ended September 30, 2026, on IPO proceeds. The report confirms utilisation is per the offer document, with no deviation from objects.
Valencia India Other Announcement
Valencia India reported no deviation in IPO fund use for six months ended September 2026. The Audit Committee-reviewed Regulation 32 statement was filed with BSE.
Neogen Chemicals Other Announcement
Neogen reports no deviation in QIP fund utilisation for the quarter ended September 30, 2026. This is a periodic utilisation report, not a new transaction.
GAMCO Other Announcement
Gamco Ltd filed its half-yearly related party transactions disclosure under Regulation 23(9) for the period ended 30 September 2026. The filing is a periodic cumulative statement with no new transaction or board decision.
- Execution
- Half year ended 30 September 2026